To further elucidate the association between circulating IGF‐I concentrations and bladder cancer risk, more data from both prospective and Mendelian randomisation studies are needed, preferably with data on tumour subtypes and aggressiveness to compare study results and ultimately conduct pooled analysis with a larger sample size. This evidence concerns the gene IGF1 and urinary bladder carcinoma.